Dublin, May 16, 2023 (GLOBE NEWSWIRE) -- The "Asia-Pacific Next-generation Diagnostics Outlook, 2023" report has been added to ResearchAndMarkets.com's offering.
The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing.
Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus on breakthrough innovation, diagnostic services must be revamped to meet reduced price points for low-resource settings.
The pandemic led to a greater focus on preventive diagnosis. Innovation in product development, a focus on care delivery and business models, and the need for more convenient sampling are leading to a paradigm shift to minimally invasive tests. Global IVD powerhouses remain at the vanguard of this transformation.
Prominent market participants are Roche Diagnostics, Abbott Laboratories, Danaher Corporation, Siemens Healthineers, and Sysmex Corporation, while regional IVD powerhouses are making a strategic shift to leverage the platform-as-a-service business model, implying momentum in secured and connected open development platforms to support rapid and standardized assay development.
Trends point toward a focus on infectious diseases outside COVID-19, molecular oncology, cardiovascular disease, and diabetes, with an emerging focus on noninvasive prenatal testing (NIPT).
Key Topics Covered:
1 Analysis Highlights
- Study Highlights
- Top Next-generation Diagnostics Industry Predictions - 2023
2 Strategic Imperatives
- Why is it Increasingly Difficult to Grow?
- The Strategic Imperative
- The Impact of the Top 3 Strategic Imperatives on the Next-generation Diagnostics Industry
- Growth Opportunities Fuel the Growth Pipeline Engine
3 Growth Environment
- Segmentation
- Growth Environment
4 Macroeconomic Factors
- Top 5 Global Economic Highlights - 2023
- Global GDP Growth Snapshot
- Advanced Economies' Predictions - 2023
- Emerging Economies' Predictions - 2023
- Regional Risks and Policy Direction - 2023
- Supply Chain Disruptions - Impact Analysis
- Innovation - Impact Analysis
- Commercial Success - Impact Analysis
5 Revenue Trends
- Revenue Forecast by Segment
- Competitive Environment
- Revenue Share
- Revenue Share Analysis
- Revenue Forecast by Country
- Revenue Forecast Analysis by Country
6 Top Predictions
- Prediction 1 - Infectious Disease Testing will Largely Transition to POC Rapid Tests
- Prediction 2 - Comprehensive POCT Solutions in Diabetes Care will Proliferate to Empower Fast Clinical Decision Making
- Prediction 3 - A Spike in Population-sequencing Efforts Will Drive NGS Market Expansion
- Prediction 4 - Demand for Cardiac Biomarker Testing in Hospitals will Drive Clinical Chemistry and Immunoassay Market Growth in China
7 Next-generation Diagnostics Segment Outlook
- Market Snapshot - 2023
- Market Snapshot - Clinical Chemistry and Immunoassays
- Market Snapshot - Molecular Diagnostics
- Market Snapshot - POCT
8 Growth Opportunity Universe
- Growth Opportunity 1: POC Rapid Testing
- Growth Opportunity 2: NIPT
- Growth Opportunity 3: Comprehensive Cancer Genomic Profiling Services
9 Conclusions
A selection of companies mentioned in this report includes
- Abbott Laboratories
- Danaher Corporation
- Roche Diagnostics
- Siemens Healthineers
- Sysmex Corporation
For more information about this report visit https://www.researchandmarkets.com/r/2ynhmd
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
